to its investors that increases over time. The REIT has certainly succeeded in that mission over the years. It has raised its ...

MPM BioImpact fully exited its position in Crinetics Pharmaceuticals during the third quarter, a move disclosed in the fund’s ...

One fund just walked away from a rising offshore driller—here’s what long-term investors should make of the move.

AMD's growth has been accelerating, and its chips have been attracting the attention of leading artificial intelligence (AI) ...

Ford has a serious profit machine that many investors overlook, but a close rival is catching on and gearing up for an ...

A fast-growing niche segment may be the real reason this small-cap consumer products stock is drawing new institutional ...

One small fund’s high-conviction move offers a window into how specialists are navigating 2025’s biotech rally.

Harrow’s accelerating revenue and expanding product portfolio may help explain why a fundamentals-focused investment firm ...

Schulman has wasted little time in making a big shakeup, with the company recently announcing that it will be laying off ...

Walmart's results showcase the nuances of purchasing decisions. Often, consumers don't eliminate a purchase, but shift the ...

A lot can change in five years. Take Vertex Pharmaceuticals ( VRTX +0.57%), for example. In late 2020, the big biotech ...

This private-equity-style shop trimmed its position in a financial technology firm that's posting record numbers despite a ...